9/20/18: Brian Pedlar, Chief Executive Officer of Covalon, said, “I am very excited about this acquisition – AquaGuard’s experienced sales team and specialized product line are a perfect synergistic fit for Covalon’s business. AquaGuard’s talented sales team has built strong relationships with clinicians and hospital staff throughout the United States that make decisions on the very same products Covalon makes – vascular access dressings, surgical site management products, and advanced wound care dressings.”
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it has engaged MPA Morrison Park Advisors Inc. (“MPA”) as a financial advisor to help the Company accelerate its growth...
Covalon Technologies reports the Offering comprises approximately 931,121 units at a price of $1.96 per unit for aggregate gross proceeds of $1,825,000. Each unit is comprised of one common share and one common share purchase warrant.
Covalon notes in a third party in vitro simulated vascular insertion study designed to measure the levels of particulate, Covalon’s Centaur ™ coating resulted in statistically significantly lower levels for all particulate sizes relative to the same uncoated catheter.